EIKN

Eikon Therapeutics, Inc. Common Stock

NASDAQ: EIKN · HEALTHCARE · BIOTECHNOLOGY

$12.31

-11.03% today

Updated 2026-06-02

Market cap

$485.08M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-6.32

Dividend yield

—

52W range

$8 – $17

Volume

0.3M

Market cap

$485.08M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-6.32

Dividend yield

—

52W range

$8 – $17

Volume

0.3M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

6.0

Quality

3.0

Profitability

5.0

Valuation

C+

2/9

Piotroski F-Score

Weak

-3.5

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →202 stocks currently score above 75

Price targets

Analyst target

$24.80

+101.46%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

2 Strong Buy3 Buy0 Hold1 Sell0 Strong Sell

Price chart

Stock snapshot

Strengths

+ Debt/equity 0.46x — low leverage

Risks

- Piotroski 2/9 — weak financial health

- Altman Z -3.45 — distress zone

- Thin margins at 0.00%

- Negative free cash flow $-90.06M

Key financials

Revenue Net Income Free Cash Flow

Metric	2023	2024	2025	TTM
Revenue	$0.00	$0.00	$0.00	$0.00
Net income	$-242.00M	$-243.81M	$-324.25M	$-82.96M
EPS	—	—	—	$-6.32
Free cash flow	$-219.36M	$-219.60M	$-235.26M	$-90.06M
Profit margin	—	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
EIKN	$485.08M	32	4.3	3.0	5.0	6.0	—	Avoid
LLY	$948.95B	78	10.0	10.0	5.0	6.0	—	Strong Buy
JNJ	$536.54B	59	4.7	9.0	3.3	6.0	-71.41%	Buy
ABBV	$380.57B	63	4.0	8.0	4.0	5.0	-55.64%	Buy
UNH	$343.21B	54	5.3	5.5	4.7	5.5	-26.61%	Buy
MRK	$285.64B	50	3.3	8.0	2.7	5.0	-49.34%	Hold

Smart narrative

Eikon Therapeutics, Inc. Common Stock trades at $12.31. Our Smart Value Score of 32/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of -3.45, it sits in the distress.

Frequently asked questions

What is Eikon Therapeutics, Inc. Common Stock's stock price?

Eikon Therapeutics, Inc. Common Stock (EIKN) trades at $12.31.

Is Eikon Therapeutics, Inc. Common Stock overvalued?

Eikon Therapeutics, Inc. Common Stock carries a Smart Value Score of 32/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.

What is the price target of Eikon Therapeutics, Inc. Common Stock (EIKN)?

The 12-month analyst consensus target is $24.80, about 101.5% above the current $12.31. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.

Altman Z-Score?

Eikon Therapeutics, Inc. Common Stock's Altman Z-Score is -3.45, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio—

ROE-53.71%

Beta—

50D MA$10.40

200D MA$11.77

Shares out0.05B

Float0.03B

Short ratio—

Avg volume0.3M

Performance

1 week+0.00%

1 month-22.01%

3 months-16.23%

YTD—

1 year—

3 years—

5 years—

Compare

EIKN vs LLY →EIKN vs JNJ →EIKN vs ABBV →Stock screener →